EP1581212A4 - Superoxide dismutase mimics for the treatment of ocular disorders and diseases - Google Patents

Superoxide dismutase mimics for the treatment of ocular disorders and diseases

Info

Publication number
EP1581212A4
EP1581212A4 EP03796677A EP03796677A EP1581212A4 EP 1581212 A4 EP1581212 A4 EP 1581212A4 EP 03796677 A EP03796677 A EP 03796677A EP 03796677 A EP03796677 A EP 03796677A EP 1581212 A4 EP1581212 A4 EP 1581212A4
Authority
EP
European Patent Office
Prior art keywords
diseases
treatment
superoxide dismutase
ocular disorders
dismutase mimics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03796677A
Other languages
German (de)
French (fr)
Other versions
EP1581212A2 (en
Inventor
Peter G Klimko
Robert J Collier
Mark R Hellberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of EP1581212A2 publication Critical patent/EP1581212A2/en
Publication of EP1581212A4 publication Critical patent/EP1581212A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP03796677A 2002-12-06 2003-12-05 Superoxide dismutase mimics for the treatment of ocular disorders and diseases Withdrawn EP1581212A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43140102P 2002-12-06 2002-12-06
US431401P 2002-12-06
PCT/US2003/038678 WO2004052227A2 (en) 2002-12-06 2003-12-05 Superoxide dismutase mimics for the treatment of ocular disorders and diseases

Publications (2)

Publication Number Publication Date
EP1581212A2 EP1581212A2 (en) 2005-10-05
EP1581212A4 true EP1581212A4 (en) 2008-11-05

Family

ID=32507723

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03796677A Withdrawn EP1581212A4 (en) 2002-12-06 2003-12-05 Superoxide dismutase mimics for the treatment of ocular disorders and diseases

Country Status (9)

Country Link
US (2) US20060089343A1 (en)
EP (1) EP1581212A4 (en)
JP (1) JP2006510669A (en)
CN (1) CN1717234A (en)
AU (1) AU2003298917A1 (en)
BR (1) BR0317026A (en)
CA (1) CA2505608A1 (en)
MX (1) MXPA05005240A (en)
WO (1) WO2004052227A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2397067B (en) * 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
GB2415372A (en) 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
AU2005287343A1 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
US20060252107A1 (en) * 2005-02-22 2006-11-09 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
US20090170841A1 (en) 2007-04-20 2009-07-02 Acucela Inc. Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders
AU2008271051C1 (en) 2007-06-29 2012-10-04 Acucela Inc. Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
CA2701116C (en) 2007-10-05 2013-02-05 Acucela Inc. Alkoxy compounds for disease treatment
US9072729B2 (en) * 2008-01-30 2015-07-07 Agency For Science, Technology And Research Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds
EP2803356A1 (en) * 2008-03-31 2014-11-19 Agency for Science, Technology and Research Method for treating neurological disorders with imidazolium and imidazolinium compounds
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
CA2777827C (en) 2009-10-30 2020-08-18 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
PT2433640T (en) 2010-09-24 2020-04-03 Omnivision Gmbh Composition comprising sod, lutein and zeaxanthin
KR102020579B1 (en) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 Impaired energy processing disorders and mitochondrial deficiency
WO2012148929A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Disorders implicating pufa oxidation
AU2012249921B2 (en) * 2011-04-26 2017-06-08 Biojiva Llc Oxidative retinal diseases
KR102020611B1 (en) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 Neurodegenerative disorders and muscle diseases implicating pufas
EP2804605A4 (en) 2012-01-20 2015-07-08 Acucela Inc Substituted heterocyclic compounds for disease treatment
WO2014064697A1 (en) * 2012-10-25 2014-05-01 Technion Research And Development Foundation Ltd. Method of treatment of disease
WO2014164905A1 (en) 2013-03-12 2014-10-09 Acucela Inc. Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders
ES2871130T3 (en) 2015-11-23 2021-10-28 Retrotope Inc Site-specific isotopic labeling of 1,4-diene systems
EP4107163A1 (en) 2020-02-21 2022-12-28 Retrotope, Inc. Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999023097A1 (en) * 1997-11-03 1999-05-14 Duke University Substituted porphyrins
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
TW325997B (en) * 1993-02-02 1998-02-01 Senju Pharma Co Pharmaceutical composition for preventing and treating retinal diseases
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6180620B1 (en) * 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
GB9817845D0 (en) * 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
MXPA01007451A (en) * 1999-01-25 2004-03-10 Nat Jewish Med & Res Center Substituted porphyrins.
WO2002098431A1 (en) * 2001-06-01 2002-12-12 National Jewish Medical And Research Center Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
WO1999023097A1 (en) * 1997-11-03 1999-05-14 Duke University Substituted porphyrins

Also Published As

Publication number Publication date
BR0317026A (en) 2005-10-25
MXPA05005240A (en) 2005-07-25
EP1581212A2 (en) 2005-10-05
JP2006510669A (en) 2006-03-30
WO2004052227A2 (en) 2004-06-24
US20060089343A1 (en) 2006-04-27
CA2505608A1 (en) 2004-06-24
US20040116403A1 (en) 2004-06-17
AU2003298917A1 (en) 2004-06-30
WO2004052227A3 (en) 2005-03-31
CN1717234A (en) 2006-01-04

Similar Documents

Publication Publication Date Title
EP1581212A4 (en) Superoxide dismutase mimics for the treatment of ocular disorders and diseases
IL291162A (en) Isolated human rpe cells and use thereof for the treatment of degenerative diseases of the retina
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
IL178142A0 (en) Methods of using and compositions comprising immunomodulatory compounos for the treatment and management of skin diseases or disorders
EP1455778A4 (en) Methods for the treatment of peripheral neural and vascular ailments
IL157364A0 (en) Therapeutic methods and agents for diseases associated with decreased expression of aop-1 gene or aop-1
IL176227A0 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
EP1753445A4 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
EP1392292A4 (en) Pyranoindazoles and their use for the treatment of glaucoma
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
IL182574A0 (en) Gpr41 and modulators thereof for the treatment of insulin-related disorders
NO20054913D0 (en) Use of clustein for the treatment and / or prevention of peripheral neurological disorders
EP1636160A4 (en) Novel therapeautic agents for the treatment of cancer, metabolic diseases and skin disorders
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
GB0523961D0 (en) The treatment of ophthalmic diseases
AU2003209150A8 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
EP1773882A4 (en) Diagnosis and treatment of siglec-6 associated diseases
ZA200603347B (en) Superoxide dismutase mimics for the treatment of optic nerve and retinal damage
ZA200400210B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
AU2003243405A1 (en) Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain
HUP0103017A3 (en) Pharmaceutical composition for the treatment of diseases caused by impairment of cognitive functions and its use
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
GB0523964D0 (en) The treatment of ophthalmic diseases
EP1488800A4 (en) Agent for the treatment of protozoal diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050506

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1084315

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20081009

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/409 20060101AFI20050512BHEP

Ipc: A61P 27/02 20060101ALI20081003BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090208

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1084315

Country of ref document: HK